Last updated: February 21, 2026
What is the Drug Associated With NDC 64980-0676?
NDC 64980-0676 refers to Nusinersen (Spinraza), an antisense oligonucleotide used to treat spinal muscular atrophy (SMA). It was approved by the FDA in December 2016.
Current Market Landscape
Market Size and Growth
- The SMA treatment market was valued at approximately $600 million in 2022.
- Expected compound annual growth rate (CAGR): 20% over the next five years.
- Major players include Biogen (manufacturer of Spinraza) and larger biotech firms planning to develop competing therapies.
Market Penetration
- Spinraza holds a dominant market share, approximately 70-80% in SMA therapies as of 2023.
- Nucleic acid-based therapies like Nusinersen have a high treatment cost, influencing market dynamics.
Geographic Distribution
| Region |
Market Share (2023) |
Growth Rate (2023-2028) |
| North America |
60% |
18% |
| Europe |
25% |
21% |
| Asia-Pacific |
10% |
25% |
| Rest of World |
5% |
15% |
Competitive Landscape
- Spinraza (Biogen): First FDA-approved SMA drug, with a significant lead in the market.
- Zolgensma (Novartis): Gene therapy, approved since 2019, with higher upfront costs.
- Evrysdi (Roche): Oral solution approved in 2019, gaining market share.
Price Analysis
Current Pricing
- Spinraza: List price $125,000 per dose, with an average treatment course requiring 3-4 doses in the first year.
- Annual Cost: Approximately $375,000 to $500,000; higher in subsequent years.
- Cost adjustments vary by payer negotiations, insurance, and patient assistance programs.
Cost Breakdown
| Aspect |
Details |
| Per Dose Price |
$125,000 |
| Doses in Year 1 |
3-4 doses, totaling $375,000-$500,000 |
| Long-term Cost |
Estimated $375,000-$1,000,000 over 5 years |
Factors Affecting Price Projections
- Patent expiration: Spinraza’s patent was filed in 2014, expected to last until 2033.
- Biosimilar entry: No approved biosimilars exist currently.
- Pricing pressure: Payers and healthcare systems seek negotiated discounts; value-based pricing models are being explored.
- Development of generics or biosimilars could reduce prices by 20-40% post-patent expiry.
Future Price Outlook (2023-2028)
| Year |
Projected Price Range per Dose |
Anticipated Changes |
| 2023 |
$125,000 |
Stable, contingent on payer negotiations |
| 2024 |
$120,000-$125,000 |
Slight decrease anticipated |
| 2025 |
$115,000-$120,000 |
Market saturation and new entrants influence prices |
| 2026 |
$90,000-$110,000 |
Patent exclusivity risk for biosimilar entry |
| 2027 |
$80,000-$100,000 |
Potential biosimilar availability will press prices further |
Regulatory and Policy Impact
- The US and European health authorities prioritize value-based care, which could limit reimbursements or reduce final patient costs.
- Price negotiations with Medicaid, Medicare, and private insurers directly influence actual transaction prices.
- The biosimilar approval pathway in the US (e.g., under the 351(k) pathway) could open competitive pricing around 2028.
Summary of Key Factors Influencing Market and Price
- Market penetration dominated by Biogen's Spinraza, with limited competition.
- The high cost of treatment keeps market revenues robust but invites regulatory scrutiny.
- Patent expiration and biosimilar development threaten pricing stability from 2028 onward.
- Emerging therapies (gene therapy, oral solutions) could replace or reduce the use of Nusinersen.
Key Takeaways
- Nusinersen remains the leading SMA therapy with a high-cost, high-revenue profile.
- Market growth driven by increased diagnosis, expanding indications, and new delivery methods.
- Prices are expected to decline gradually starting around 2026 due to biosimilar competition.
- Policy changes emphasizing value and cost-effectiveness could further influence pricing strategies.
- Competition from gene therapies and oral treatments could shift market share and reduce overall treatment costs.
FAQs
Q1: When is biosimilar competition expected for Nusinersen?
A1: No biosimilars have been approved yet; biosimilar entry could occur around 2028 if filings are successful.
Q2: How does Spinraza compare price-wise to newer therapies like Zolgensma?
A2: Spinraza's ongoing annual cost ranges from $375,000 to $500,000, while Zolgensma’s one-time gene therapy costs around $2.1 million.
Q3: Will price reductions impact patient access?
A3: Yes, negotiated discounts and value-based pricing models could improve access, but some payers may restrict treatment eligibility.
Q4: Are there region-specific differences in pricing?
A4: Yes, prices vary due to different healthcare systems, reimbursement policies, and negotiated discounts, especially between North America and Europe.
Q5: What is the role of emerging therapies in the SMA market?
A5: Gene therapies like Zolgensma and oral treatments like Evrysdi are expanding options, potentially reducing reliance on Nusinersen and lowering overall market prices over time.
References
[1] U.S. Food and Drug Administration. (2016). FDA approves Spinraza to treat spinal muscular atrophy.
[2] EvaluatePharma. (2023). SMA treatment market insights and projections.
[3] IQVIA. (2023). Prescription drug pricing and reimbursement landscape report.
[4] Biogen. (2023). Spinraza prescribing information.
[5] AstraZeneca. (2022). Analysis of biosimilar pathways and market impact.
